<DOC>
	<DOCNO>NCT00752973</DOCNO>
	<brief_summary>In previous phase II study , safety efficacy novel formulation malathion 0.5 % evaluate patient 2 year age old . Based result study , formulation currently phase III study population . The current study use blood marker clinical evaluation determine safety tolerability formulation use child 6-24 month age .</brief_summary>
	<brief_title>Safety Tolerability Novel Malathion Formulation Children Age 6-24 Months With Head Lice</brief_title>
	<detailed_description />
	<mesh_term>Lice Infestations</mesh_term>
	<mesh_term>Malathion</mesh_term>
	<criteria>Confirmed active head louse infestation Allergy pediculicides hair care product Scalp condition head lice Previous head louse treatment within past 4 week Current antibiotic treatment</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Head Lice</keyword>
</DOC>